drugset / Trial / NCT05924594

Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301

NCT05924594

Phase 3 Suspended 45 enrolled Cingulate Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in children (6-12) with ADHD in a laboratory classroom setting.

Timeline

Start
2023-07-31
Primary completion
2027-02
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject dexmethylphenidate Unknown 6.25 mg
Subject dexmethylphenidate Unknown 12.5 mg
Subject dexmethylphenidate Unknown 18.75 mg
Subject dexmethylphenidate Unknown 25 mg
Subject dexmethylphenidate Unknown 31.25 mg
Subject dexmethylphenidate Unknown 37.5 mg